Drugs / RINUCUMAB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02418754 | May 2015 → Aug 2016 | wet macular degeneration | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RINUCUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545316 ↗ |
| Known as | REGN2176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02418754 ↗ |
| Action | Inhibit | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL3545316 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3545316 ↗ |
| Route | Intravitreal | “Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks.” NCT02418754 ↗ |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL3545316 ↗ |